Advanced Viral Research Corp. Hires Public Relations Firm
Advanced Viral Research Corporation (OTCBB: ADVR), a research based biopharmaceutical company dedicated to anti-cancer drug discovery and development, announced today it has appointed the life sciences marketing communications firm The Signature Agency to assist in its overall branding and investor communications.
Advanced Viral Research Corporation is developing a new class of cytoprotective drug which may be useful in the treatment of cachexia (body wasting), appetite loss, and lethargy in patients with cancer and HIV-AIDS. The compound also is being evaluated in a Phase II topical wound healing study after demonstrating accelerated wound healing properties in a well established animal model at the University of Miami.
The Signature Agency, a full-service North Carolina based public relations agency, provides a wide range of services that include corporate communications, investor relations, web-site design and product marketing strategies.
“The Signature Agency will assist us in providing superior service to our stakeholders by keeping them better informed of the issues and events that impact our growth,” said Stephen M. Elliston, President and Chief Executive Officer.
Advanced Viral Research Corp. is a New York based biopharmaceutical company dedicated to improving patients' lives by researching, developing and bringing to market new and effective therapies for the control of symptoms associated with cancer and other serious diseases. Its initial compound AVR118 represents a new class of cytoprotective agent that targets among other things, cachexia related disorders. AVR118 has also shown to have topical wound healing properties in animal models. Various degenerative conditions associated with body wasting (cachexia) such as cancer, HIV-AIDS and chronic inflammation are potential disease targets for AVR118 therapy. |
